One To Watch

Illumina

A global life science technology company headquartered in the United States. It sells next-generation sequencing (NGS) systems, consumables, microarrays, and bioinformatics software to research institutions, clinical laboratories, biopharma companies, and population genomics programs worldwide.

Founding and History

Illumina was founded in 1998 and is publicly traded on Nasdaq (ILMN). The company became the dominant supplier of short-read DNA sequencing platforms through successive system generations and a high-consumables, instrument-anchored business model. In recent years, Illumina has pushed further into clinical genomics and multiomics, alongside expanded informatics offerings.

Therapy Areas and Focus

Illumina is not a drug developer. Its products enable applications across:

Human genetics and population genomics
Oncology and minimal residual disease testing workflows
Reproductive and genetic health
Infectious disease surveillance and microbiology
Translational research and drug discovery, including multiomics and proteomics-enabled workflows

Technology Platforms and Modalities

Illumina’s core business is sequencing-by-synthesis–based NGS, supported by informatics and sample-to-answer workflows.

Key platform components include:

Sequencing systems spanning production-scale and benchtop throughput tiers (including the NovaSeq X series, NextSeq series, and MiSeq family)
Array-based genotyping for large-scale screening and research
Bioinformatics software and cloud/on-prem secondary analysis, including DRAGEN pipelines and Illumina Connected Analytics, used for alignment, variant calling, and downstream interpretation
Clinical assays and workflows designed for regulated and near-regulated environments, including oncology-focused testing products

Strategic Partnerships

Illumina’s partnership model is ecosystem-driven. It works with clinical laboratories, national genomics initiatives, biopharma companies, and bioinformatics partners to expand validated applications and increase adoption of sequencing in routine healthcare. The company also uses M&A selectively to add capabilities in adjacent omics domains and clinical decision support.

FAQ Section

Illumina designs and sells sequencing instruments and the consumables that run on them, alongside bioinformatics software used to process and interpret genomic data. The recurring consumables stream is central to its economics and installed-base strategy.

Illumina’s largest markets are life science research and clinical genomics. Customer segments include academic and government research, clinical labs, biopharma R&D, population genomics programs, and public health organizations.

Illumina’s portfolio includes sequencing systems (from benchtop to production-scale), sequencing consumables, genotyping arrays, and informatics products (notably DRAGEN and Connected Analytics). The company also markets clinical-oriented assays, particularly in oncology.

Recent developments have included completion of the SomaLogic acquisition (expanding Illumina’s multiomics and proteomics positioning), launch of a new BioInsight business unit discussed at the JPM 2026 conference, and commercial progress tied to reimbursement coverage for an oncology comprehensive genomic profiling test. Illumina has also announced initiatives intended to support AI and drug discovery use cases, including a “Billion Cell Atlas” program.

Illumina positions its current flagship systems around higher throughput, lower cost per genome at scale, and improved operational automation, while emphasizing data quality and compatibility with established clinical and research workflows.

Illumina’s instruments are predominantly sold for research use, but the company also supports clinical deployment through regulated assays and partnerships with laboratories running validated tests. Reimbursement and clinical guideline inclusion are key levers for expanding clinical sequencing adoption, especially in oncology.

Illumina is led by a public-company executive team spanning product development, commercial operations, finance, and clinical strategy. Recent leadership additions have emphasized clinical genomics, reflecting the company’s focus on expanding sequencing from research into routine care.

Want to Update your Company's Profile?